Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes

Sabrina Lyngbye Wendt, Ajenthen Ranjan, Jan Kloppenborg Møller, Signe Schmidt, Carsten Boye Knudsen, Jens Juul Holst, Sten Madsbad, Henrik Madsen, Kirsten Nørgaard, John Bagterp Jørgensen

Research output: Contribution to conferencePosterResearch

292 Downloads (Pure)

Abstract

Currently, no consensus exists on a model describing endogenous glucose production (EGP) as a function of glucagon concentrations. Reliable simulations to determine
the glucagon dose preventing or treating hypoglycemia or to tune a dual-hormone artificial pancreas control algorithm need a validated glucoregulatory model including the effect of glucagon.
Original languageEnglish
Publication date2017
Number of pages1
Publication statusPublished - 2017
EventAdvanced Technology and Treatments for Diabetes 2017 - Paris, France
Duration: 15 Feb 201718 Feb 2017

Conference

ConferenceAdvanced Technology and Treatments for Diabetes 2017
CountryFrance
CityParis
Period15/02/201718/02/2017

Cite this

Wendt, S. L., Ranjan, A., Møller, J. K., Schmidt, S., Boye Knudsen, C., Holst, J. J., ... Jørgensen, J. B. (2017). Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes. Poster session presented at Advanced Technology and Treatments for Diabetes 2017, Paris, France.
Wendt, Sabrina Lyngbye ; Ranjan, Ajenthen ; Møller, Jan Kloppenborg ; Schmidt, Signe ; Boye Knudsen, Carsten ; Holst, Jens Juul ; Madsbad, Sten ; Madsen, Henrik ; Nørgaard, Kirsten ; Jørgensen, John Bagterp. / Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes. Poster session presented at Advanced Technology and Treatments for Diabetes 2017, Paris, France.1 p.
@conference{32a8110aaeac4ba5974e47325de683bf,
title = "Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes",
abstract = "Currently, no consensus exists on a model describing endogenous glucose production (EGP) as a function of glucagon concentrations. Reliable simulations to determinethe glucagon dose preventing or treating hypoglycemia or to tune a dual-hormone artificial pancreas control algorithm need a validated glucoregulatory model including the effect of glucagon.",
author = "Wendt, {Sabrina Lyngbye} and Ajenthen Ranjan and M{\o}ller, {Jan Kloppenborg} and Signe Schmidt and {Boye Knudsen}, Carsten and Holst, {Jens Juul} and Sten Madsbad and Henrik Madsen and Kirsten N{\o}rgaard and J{\o}rgensen, {John Bagterp}",
year = "2017",
language = "English",
note = "Advanced Technology and Treatments for Diabetes 2017, ATTD 2017 ; Conference date: 15-02-2017 Through 18-02-2017",

}

Wendt, SL, Ranjan, A, Møller, JK, Schmidt, S, Boye Knudsen, C, Holst, JJ, Madsbad, S, Madsen, H, Nørgaard, K & Jørgensen, JB 2017, 'Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes', Advanced Technology and Treatments for Diabetes 2017, Paris, France, 15/02/2017 - 18/02/2017.

Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes. / Wendt, Sabrina Lyngbye; Ranjan, Ajenthen; Møller, Jan Kloppenborg; Schmidt, Signe; Boye Knudsen, Carsten; Holst, Jens Juul; Madsbad, Sten; Madsen, Henrik; Nørgaard, Kirsten; Jørgensen, John Bagterp.

2017. Poster session presented at Advanced Technology and Treatments for Diabetes 2017, Paris, France.

Research output: Contribution to conferencePosterResearch

TY - CONF

T1 - Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes

AU - Wendt, Sabrina Lyngbye

AU - Ranjan, Ajenthen

AU - Møller, Jan Kloppenborg

AU - Schmidt, Signe

AU - Boye Knudsen, Carsten

AU - Holst, Jens Juul

AU - Madsbad, Sten

AU - Madsen, Henrik

AU - Nørgaard, Kirsten

AU - Jørgensen, John Bagterp

PY - 2017

Y1 - 2017

N2 - Currently, no consensus exists on a model describing endogenous glucose production (EGP) as a function of glucagon concentrations. Reliable simulations to determinethe glucagon dose preventing or treating hypoglycemia or to tune a dual-hormone artificial pancreas control algorithm need a validated glucoregulatory model including the effect of glucagon.

AB - Currently, no consensus exists on a model describing endogenous glucose production (EGP) as a function of glucagon concentrations. Reliable simulations to determinethe glucagon dose preventing or treating hypoglycemia or to tune a dual-hormone artificial pancreas control algorithm need a validated glucoregulatory model including the effect of glucagon.

M3 - Poster

ER -

Wendt SL, Ranjan A, Møller JK, Schmidt S, Boye Knudsen C, Holst JJ et al. Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes. 2017. Poster session presented at Advanced Technology and Treatments for Diabetes 2017, Paris, France.